Knowing the status of your patient’s BRCA 1/2 germline status is critical. Myriad hereditary cancer tests give you definitive and actionable risk stratification insights that directly impact current and future treatment decisions. Integrating germline testing early in your patients’ diagnostic workup is now easier than ever.

Patients with localized prostate cancer and a BRCA mutation are:

  • 6x more likely to die from prostate cancer within 5 years
  • 4x more likely to develop metastasis within 5 years
  • Live ~7 years less on average

If you would like to learn more about BRACAnalysis CDx® or myRisk®, click here.